---
title: Antiplatelets
author: J. Austin Straley, DO
layout: post
date: 2023-03-30
permalink: /antiplatelets
categories:
    - Heme/Onc
    - Pharmacology
---
## 1) Antiplatelet Drugs
  - COX Inhibitors
  - Prostaglandin Analogues (PGI2)
    - Treprostinil (Remoodulin)
  - Combos
    - Aspirin + Clopidogrel
      - 4 weeks after bare metal stent
      - 6 months after drug eluting stent
      - Unstable angina
    - Aspirin + Prasugrel
      - Patients undergoing PCI

## A) COX Inhibitors
- Acetylsalicylic Acid (Aspirin)
  - COX1 Inhibition (Thromboxane A2)
  - COX2 Inhibition at high doses
  - Overdose:
    - Gastric Lavage, Activated Charcoal
    - Alkalinization of the urine (IV Sodium Bicarb)
      - Goal of urine pH ≥7.5
    - Dialysis if Salicylate levels ≥90-100 with acute intoxication or ≥60 ng/mL in chronic administration
  - Reye Syndrome
    - Use of aspirin after a URI
    - Symptoms
      - Acute encephalopathy w/hepatic dysfunction occurring days after recovery
      - Heavy vomiting, delirium, fatty liver, seizures, coma
    - Liver failure with elevated AST, ALT
    - Increased PT, elevated ammonia, and hypoglycemia
    - +/- Renal and heart failure, Increased ICP

## B) PDE Inhibitors/Thromboxane Inhibitors
- Cyclic AMP Interference
- Dipyridamol (Persantine)
  - Blocks AMP BD, inhibit Platelet activation

## C) PARI
- Thrombin Receptor Interference, PAR-1 Antagonist
- Vorapaxar (Zontivity)

## D) P2Y12
- ADP Receptor Antagonists (P2Y12 Inhibitors)
  - Binds platelet ADP receptor
    - Inhibits platelet aggregation
    - Used in aspirin intolerant or in coronary stents
- Thienopyridine (IR)
    - Require CYP450 activation
  - Clopidogrel (Plavix)
  - Prasugrel (Effient)
    - 10x stronger, more rapid
    - More bleeding risk than clopidogrel
    - CI in ≥75 y/o, renal impaired, CVD
  - Ticlopidine (Ticlid)
- Nucleotide/side analog (R)
    - Reversible, no activation needed to work
  - Ticagrelor (Brilinta)
    - More rapid onset, ≥ than clopidogrel
    - SE: Dyspnea MC
  - Cangrelor
    - Immediate onset – 1 hour

## E) GIIb/IIIa Receptor Inhibitors
- GP IIb/IIIa antagonists
  - Abciximab (ReoPro)
    - PCI w/o ADPRA, not renally cleared
    - Monoclonal antibody
  - Eptifibatide (Integrilin)
  - Tirofiban (Aggrastat)
    - High risk unstable angina- Eptifibutide (Integrilin)

## F) PDE3 Inhibitors
- Cilostazole (Pletal)
  - Only indicated in symptomatic claudication
  - CI: HF